Cadinha & Co. LLC Sells 12,813 Shares of Eli Lilly and Company $LLY

Key Points

• Cadinha & Co. LLC reduced its stake in Eli Lilly by 68.2%, selling 12,813 shares and now holds 5,982 shares valued at approximately $4.66 million.
• Several hedge funds have adjusted their holdings in Eli Lilly, with Precedent Wealth Partners LLC increasing its position by 15.3%, highlighting strong institutional interest in the company.
• Analysts have given Eli Lilly a consensus price target of $938.61, with ratings ranging from Strong Buy to Hold.

Cadinha & Co. LLC cut its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 68.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,982 shares of the company's stock after selling 12,813 shares during the quarter. Eli Lilly and Company makes up about 0.8% of Cadinha & Co. LLC's investment portfolio, making the stock its 25th largest position. Cadinha & Co. LLC's holdings in Eli Lilly and Company were worth $4,663,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the business. Precedent Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 15.3% in the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company's stock worth $229,000 after buying an additional 39 shares during the period. Capital Advisors Inc. OK lifted its holdings in Eli Lilly and Company by 6.8% in the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company's stock worth $5,260,000 after buying an additional 429 shares during the period. Family CFO Inc bought a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $54,000. Duquesne Family Office LLC lifted its stake in Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock worth $78,321,000 after acquiring an additional 32,640 shares during the period. Finally, Corient IA LLC purchased a new position in Eli Lilly and Company during the 1st quarter valued at $570,000. 82.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

LLY has been the subject of a number of research reports. The Goldman Sachs Group increased their price target on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the stock a "buy" rating in a research note on Friday, October 10th. DZ Bank upgraded shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Wall Street Zen cut shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research report on Saturday, September 20th. Hsbc Global Res raised Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Finally, Morgan Stanley dropped their target price on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating on the stock in a report on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $938.61.

Eli Lilly and Company Price Performance

LLY stock opened at $809.72 on Thursday. The firm has a market cap of $766.36 billion, a P/E ratio of 52.85, a price-to-earnings-growth ratio of 1.14 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $935.63. The stock has a 50-day simple moving average of $762.81 and a 200-day simple moving average of $766.75.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business's quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter last year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky bought 1,000 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, with a total value of $634,400.00. Following the transaction, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. This trade represents a 0.73% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO David A. Ricks purchased 1,632 shares of the firm's stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the transaction, the chief executive officer directly owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.